Th17 Inducing Cytokines Pregnancy and After Postpartum

Pregnancy Clinical Trial

Official title:

Interleukin-17 and Th17 Inducing Cytokines Exacerbate Periodontal Disease During Pregnancy and Postpartum

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03449186
• Other study ID #: BAP-2015
• Status: Completed
• Phase: N/A
• First received: January 26, 2018
• Last updated: February 22, 2018
• Start date: April 1, 2013
• Est. completion date: January 2018

Study information

• Verified date: February 2018
• Source: Adnan Menderes University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The aim of this study was to investigate salivary and gingival crevicular fluid (GCF) levels of IL-17A, IL-17E, IL-6 AND IL-23 during 2/3 trimester of pregnancy and after delivery.

Description:

IL-17 have a synergytic effect with IL-6 and IL-23. IL-17A levels elevated with periodontal diseases. Many systemical chronic conditions such as atherosclerosis and cardiovascular disease, pregnancy may contribute increasing of IL-17 family cytokine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 114
• Est. completion date: January 2018
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 19 Years to 40 Years

Eligibility

Inclusion Criteria:

• women 2 and 3 trimester of their pregnancy

Exclusion Criteria:

• any known systemic disease,

• periodontal treatment within the last six months,

• patients having less than 10 teeth,

• smokers,

• individuals with a BMI > 30 kg/m2,

• gestational diabetes and preeclampsia during pregnancy.

Related Conditions & MeSH terms

• Pregnancy

Intervention

Other:
• Saliva collection

• GCF collection

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Adnan Menderes University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changing Il-17A levels	Salivary and GCF level measured by ELISA	6 month
Secondary	Changing IL-6 levels	Salivary and GCF level measured by ELISA	6 month
Secondary	Changing IL-23 levels	Salivary and GCF level measured by ELISA	6 month
Secondary	Changing IL-17E levels	Salivary and GCF level measured by ELISA	6 month